ArticleEndocrine-related cancer2014
miR-145 suppresses thyroid cancer growth and metastasis and targets AKT3.
Article in Endocrine-related cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The diagnostic and prognostic potential of extracellular vesicles as biomarkers for thyroid cancer: a systematic review.Journal of molecular medicine (Berlin, Germany) · 2025Pooled it
- Circulating microRNAs and Clinicopathological Findings of Papillary Thyroid Cancer: A Systematic Review.In vivo (Athens, Greece)Pooled it
- Exosomal miR-145-5p inhibits papillary thyroid cancer by targetingOncology letters · 2026Article
- Comprehensive Review of Extracellular Vesicles in Thyroid Cancer: From Methodological Approaches to Biological Functions and Clinical Applications.International journal of molecular sciences · 2026Review
- Exosome-mediated metabolic reprogramming: effects on thyroid cancer progression and tumor microenvironment remodeling.Molecular cancer · 2025Review
- 'Investigation of miRNAs That Affect the PI3K/AKT/mTOR Signaling Pathway in Endometrial Cancer'.Cell biochemistry and biophysics · 2025Article
- The effect of microRNA-145 on proliferation and apoptosis of cutaneous squamous cell carcinoma cells.Discover oncology · 2025Article
- Exosomal miRNA-based theranostics in cervical cancer: bridging diagnostics and therapy.Medical oncology (Northwood, London, England) · 2025Review
- Navigating thyroid cancer complexity: the emerging role of EV-derived non-coding RNAs.Cell death discovery · 2025Review
- Dr. Jekyll or Mr. Hyde: The multifaceted roles of miR-145-5p in human health and disease.Non-coding RNA research · 2025Review
- Circulating Biomarkers of Thyroid Cancer: An Appraisal.Journal of clinical medicine · 2025Review
- Article
- Review
- MicroRNA-181b-5p Facilitates Thyroid Cancer Growth via Targeting Programmed Cell Death 4.Molecular biotechnology · 2024Article
- The Suppression of the Epithelial to Mesenchymal Transition in Prostate Cancer through the Targeting of MYO6 Using MiR-145-5p.International journal of molecular sciences · 2024Article
- Exploring exosomes: novel diagnostic and therapeutic frontiers in thyroid cancer.Frontiers in pharmacology · 2024Review
- Exosomal noncoding RNAs: decoding their role in thyroid cancer progression.Frontiers in endocrinology · 2024Review
- Review
- Matrix Metalloproteinase 9/microRNA-145 Ratio: Bridging Genomic and Immunological Variabilities in Thyroid Cancer.Biomedicines · 2023Article
- CTC, ctDNA, and Exosome in Thyroid Cancers: A Review.International journal of molecular sciences · 2023Review
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The expression and function of miR-145 in thyroid cancer is unknown. We evaluated the expression and function of miR-145 in thyroid cancer and its potential clinical application as a biomarker. We found that the expression of miR-145 is significantly downregulated in thyroid cancer as compared with normal. Overexpression of miR-145 in thyroid cancer cell lines resulted in: decreased cell proliferation, migration, invasion, VEGF secretion, and E-cadherin expression. miR-145 overexpression also inhibited the PI3K/Akt pathway and directly targeted AKT3. In vivo, miR-145 overexpression decreased tumor growth and metastasis in a xenograft mouse model, and VEGF secretion. miR-145 inhibition in normal primary follicular thyroid cells decreased the expression of thyroid cell differentiation markers. Analysis of indeterminate fine-needle aspiration samples showed miR-145 had a 92% negative predictive value for distinguishing benign from malignant thyroid nodules. Circulating miR-145 levels were significantly higher in patients with thyroid cancer and showed a venous gradient. Serum exosome extractions revealed that miR-145 is secreted. Our findings suggest that miR-145 is a master regulator of thyroid cancer growth, mediates its effect through the PI3K/Akt pathway, is secreted by the thyroid cancer cells, and may serve as an adjunct biomarker for thyroid cancer diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.